|
Schirdewan博士的引述的參考文獻:
% V7 I) O) ~( a# @! {; P' l* A; L
' R6 `: \7 _9 V; e* KCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. / P0 x( S* y+ f8 v
" @" p! s; H- ~) l1 y$ ~& w
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 % q x* M6 L: W$ v2 `! [
6 R" k% b x5 U/ i) q8 Y
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
2 ^2 T- s7 O" v- c) G' ^* `$ O& N
V- N5 Z( r: S: [) J關於BIOTRONIK SE & Co. KG
7 p/ j$ q4 h& S9 e1 M' ~4 n& m2 V4 [8 l% b& D; f' V' G
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|